Top

Published in:

Open Access 01-04-2011 | Original Paper

The Involvement of RCAS1 in Creating a Suppressive Tumor Microenvironment in Patients with Salivary Gland Adenocarcinoma

Authors: Magdalena Dutsch-Wicherek, Agata Lazar, Romana Tomaszewska

Published in: Cancer Microenvironment | Issue 1/2011

Abstract

The tumor microenvironment is the tissue that determines the growth and progression of the tumor as well as its ability to initiate metastases. The aim of the present study has been to evaluate the role of RCAS1 in creating the suppressive tumor microenvironment in cases of parotid adenocarcinoma. The tissue samples of salivary gland adenocarcinomas and their stroma and the palatine tonsils which constituted the reference tissue sample group were obtained during routine surgical procedures. The immunoreactivity of RCAS1, CD3, CD25, CD68, CD69, and Foxp3 antigens was then evaluated by using the immunohistochemistry method. The patient’s consent was obtained in each case. A statistically significantly higher RCAS1 immunoreactivity level was found in the adenocarcinoma tissue samples in comparison to that found in the stromal tissue samples. A statistically significantly higher RCAS1 immunoreactivity was also identified in the adenocarcinoma tissue samples derived from patients who had lymph node metastases in comparison to patients without such metastases. Additionally, we observed the presence of RCAS1-positive macrophages in the stromal tissue samples. The infiltration of CD68-positive cells was significantly stronger in the adenocarcinoma and stromal tissue slides than in the reference group tissue slides; moreover, the infiltration was a good deal more prominent in the stromal tissue than in the adenocarcinoma tissue. The CD68 immunoreactivity levels in both the tumor and stromal tissue samples were found to be significantly higher in those patients who had lymph node metastases than in the patients without such metastases. Additionally, the infiltration of CD3- and CD25-positive cells was more prominent in the reference tissue slides than in the adenocarcinoma and stromal tissue slides, and was stronger in the adenocarcinoma tissue than in the stromal tissue. Furthermore, the infiltration of Foxp3-positive cells was seen exclusively in the stroma whereas it was not even detected in the adenocarcinoma tissue. Lastly, the Foxp3-positive cell infiltration was more prominent in the stromal tissue than in the reference group tissue. The present study demonstrates that RCAS1 expression by both tumor cells and tumor-associated macrophages may participate in creating the immunosuppressive microenvironment in parotid gland adenocarcinoma, thus promoting tumor development as well as metastases.

Witz IP (2009) The tumor microenvironment: the making of a paradigm. Cancer Microenvironment 2:S9–S17CrossRef

Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, Brumlik M, Cheng P, Curie T, Myers L, Lackner A, Alvarez X, Ochoa A, Chen L, Zou W (2007) B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. JEM 203:871–881

Zou W (2005) Immunosuppressive networks in the tumor microenvironment and their therapeutic relevance. Nat Rev Cancer 5:263–274PubMedCrossRef

Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867PubMedCrossRef

Sonoda K, Nakashima M, Kaku T, Kamura T, Nakano H, Watanabe T (1996) A novel tumor-associated antigen expressed in human uterine and ovarian carcinomas. Cancer 77:1501–1509PubMedCrossRef

Sonoda K, Miyamoto S, Hirakawa T, Yagi H, Yotsumoto F, Nakashima M, Watanabe T, Nakano H (2006) Clinical significance of RCAS1 as a biomarker of uterine cancer. Gynecol Oncol 103:924–931PubMedCrossRef

Sonoda K, Miyamoto S, Hirakawa T, Yagi H, Yotsumoto F, Nakashima M, Watanabe T, Nakano H (2005) Invasive potency related to RCAS1 expression in uterine cervical cancer. Gynecol Oncol 99:189–198PubMedCrossRef

Sonoda K, Miyamoto S, Kobayashi H, Ogawa S, Okugawa K, Taniguchi S, Wake N (2009) The level of RCAS1 expression is inversely correlated with the number of vimentin-positive stromal cells in epithelial ovarian cancer. Int J Gynecol Cancer 19:838–843PubMedCrossRef

Kokkinos MI, Wafai R, Wong MK, Newgreen DF, Thompson EW, Waltham M (2007) Vimentin and epithelial-mesenchymal transition in human breast cancer — observations in vitro and in vivo. Cells Tissues Organs 185:191–203PubMedCrossRef

10.

Dutsch-Wicherek M, Tomaszewska R, Lazar A, Wicherek Ł, Skladzień J (2009) The association between RCAS1 expression in laryngeal and pharyngeal cancer and its healthy stroma with cancer relapse. BMC Cancer 9:35PubMedCrossRef

11.

Dutsch-Wicherek M (2010) RCAS1, MT, and vimentin as potential markers of tumor microenvironment remodeling. Am J Reprod Immunol 63:181–188PubMedCrossRef

12.

Tsujitani S, Saito H, Oka S, Sakamoto T, Kanaji S, Tatebe S, Ikeguchi M (2002) Prognostic significance of RCAS1 expression in relation to the infiltration of dendritic cells and lymphocytes in patients with esophageal carcinoma. Dig Dis Sci 52:549–554CrossRef

13.

Fukuda K, Tsujitani S, Maeta Y, Yamaguchi K, Ikeguchi M, Kaibara N (2002) The expression of RCAS1 and tumor infiltrating lymphocytes in patients with T3 gastric carcinoma. Gastric Cancer 5:220–227PubMedCrossRef

14.

Nakamura Y, Yamazaki K, Oizumi S, Nakashima M, Watanabe T, Dosaka-Akita H, Nishimura M (2004) Expression of RCAS1 in human gastric carcinoma: a potential mechanism of immune escape. Cancer Sci 95:260–265PubMedCrossRef

15.

Oshikiri T, Hida Y, Miyamoto M, Hashida H, Katoh K, Suzuoki M, Nakakubo Y, Hiraoka K, Shinohara T, Itoh T, Kondo S, Katoh H (2001) RCAS1 as a tumor progression marker: an independent negative prognostic factor in gallbladder cancer. Br J Cancer 85:1922–1927PubMedCrossRef

16.

Hiraoka K, Hida Y, Miyamoto M, Oshikiri T, Suzuoki M, Nakakubo Y, Shinohara T, Itoh T, Shichinohe T, Kondo S, Kasahara N, Katoh H (2002) High expression of tumor-associated antigen RCAS1 in pancreatic ductal adenocarcinoma is an unfavorable prognostic marker. Int J Cancer 99:418–423PubMedCrossRef

17.

Okada T, Iiai T, Kawachi Y, Moroda T, Takii Y, Hatakeyama K, Abo T (1995) Origin of CD57+ T cells which increase at tumour sites in patients with colorectal cancer. Clin Exp Immunol 102:159–166PubMedCrossRef

18.

Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444PubMedCrossRef

19.

Sonoda K, Miyamoto S, Yotsumoto F, Yagi H, Nakashima M, Watanabe T, Nakano H (2007) Clinical significance of RCAS1 as a biomarker of ovarian cancer. Oncol Rep 17:623–628PubMed

20.

Dutsch-Wicherek M, Wicherek L (2008) The association of RCAS1 serum concentration with the reversibility or irreversibility of the process of immune cytotoxic activity restriction during normal menstrual cycle, cancer relapse, and surgical treatment for various types of squamous cell carcinomas and adenocarcinomas. Am J Reprod Immunol 59:266–275PubMedCrossRef

21.

Wicherek Ł, Dutsch M, Mak P, Klimek M, Skladzien J, Dubin A (2003) Comparative analysis of RCAS1 level in neoplasms and placenta. Acta Biochim Pol 50:1187–1194PubMed

22.

Akashi T, Oimomi H, Nishiyama K, Nakashima M, Arita Y, Sumii T, Kimura T, Ito T, Nawata H, Watanabe T (2003) Expression and diagnostic evaluation of the human tumor-associated antigen RCAS1 in pancreatic cancer. Pancreas 26:49–55PubMedCrossRef

23.

Wicherek L (2009) Alterations in RCAS1 serum concentration levels during menstrual cycle in patients with uterine leiomyoma and lack of analogical changes in adenomyosis. Gynecol Obstet Investig 67:195–201CrossRef

24.

Coban S, Ozkan H, Köklü S, Yüksel O, Koçkar MC, Akar T, Ormeci N (2006) The utility of serum receptor-binding cancer antigen expressed on SiSo cells in gastrointestinal tract cancers. Can J Gastroenterol 20:593–596PubMed

25.

Waldmann TA (1993) The IL-2/IL-2 receptor system: a target for rational immune intervention. Immunol Today 14:264–270PubMedCrossRef

26.

Baxevanis CN, Dedoussis GV, Papadopoulos NG, Missitzis I, Stathopoulos GP, Papamichail M (1994) Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer. Cancer 74:1275–1282PubMedCrossRef

27.

Parmiani G, Anichini A, Fossati G (1990) Cellular immune response against autologous human malignant melanoma: are in vitro studies providing a framework for a more effective immunotherapy? J Natl Cancer Inst 82:361–370PubMedCrossRef

28.

Parmiani G (1990) An explanation of the variable clinical response to interleukin 2 and LAK cells. Immunol Today 11:113–115PubMedCrossRef

29.

Coventry BJ, Weeks SC, Heckford SE, Sykes PJ, Bradley J, Skinner JM (1996) Lack of IL-2 cytokine expression despite Il-2 messenger RNA transcription in tumor-infiltrating lymphocytes in primary human breast carcinoma: selective expression of early activation markers. J Immunol 156:3486–3492PubMed

30.

Miescher S, Whiteside TL, Moretta L, Von Fliedner V (1987) Clonal and frequency analyses of tumor infiltrating T lymphocytes from human solid tumors. J Immunol 138:4004–4011PubMed

31.

Sheu BC, Lin RH, Ho HN, Huang SC (1997) Down-regulation of CD25 expression on the surface of activated tumor-infiltrating lymphocytes in human cervical carcinoma. Hum Immunol 56:39–48PubMedCrossRef

32.

Wyckoff J, Wang W, Lin EY, Wang Y, Pixley F, Stanley ER, Graf T, Pollard JW, Segall J, Condeelis J (2004) A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res 64:7022–7029PubMedCrossRef

33.

Pollard JW (2004) Tumor-educated macrophages promote tumor progression and metastasis. Nat Rev Cancer 4:71–78PubMedCrossRef

34.

Vakkila J, Lotze MT (2004) Inflammation and necrosis promote tumor growth. Nat Rev Immunol 4:641–648PubMedCrossRef

35.

Mantovani A, Sozzani S, Locati M, Allavena P, Sica A (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23:549–555PubMedCrossRef

36.

Mantovani A, Schioppa T, Porta C, Allavena P, Sica A (2006) Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 25:315–322PubMedCrossRef

37.

Bottazzi B, Polentarutti N, Acero R, Balsari A, Boraschi D, Ghezzi P, Salmona M, Mantovani A (1983) Regulation of the macrophage content of neoplasms by chemoattractans. Science 220:210–212PubMedCrossRef

38.

Polverini P, Leibovich SJ (1984) Induction of neovascularization in vivo and endothelial proliferation in vitro by tumor-associated macrophages. Lab Invest 51:635–642PubMed

39.

Suehiro Y, Muta K, Nakashima M, Abe Y, Shiratsuchi M, Shiokawa S, Ikuyama S, Yoshikawa Y, Watanabe T, Nishimura J (2005) A novel mechanism in suppression of erythropoiesis during inflammation: a crucial role of RCAS1. Eur J Haematol 74:365–373PubMedCrossRef

40.

Matsushima T, Nakashima M, Oshima K, Abe Y, Nishimura J, Nawata H, Watanabe T, Muta K (2001) Receptor binding cancer antigen expressed on SiSo cells, a novel regulator of apoptosis of erythroid progenitor cells. Blood 15:313–321CrossRef

41.

Enjoji M (2006) RCAS1-expressing macrophages in inflammatory liver diseases. Liver Int 26:385–387PubMedCrossRef

42.

Dutsch-Wicherek M, Tomaszewska R, Stręk P, Wicherek Ł, Składzień J (2006) The analysis of RCAS1 and DFF-45 expression in nasal polyps with respect to immune cells infiltration. BMC Immunol 7:4PubMedCrossRef

43.

Dutsch-Wicherek M, Tomaszewska R, Lazar A, Strek P, Wicherek Ł, Piekutowski K, Jóźwicki W (2010) The evaluation of metallothionein expression in nasal polyps with respect to immune cell presence and activity. BMC Immunol 11:10PubMedCrossRef

44.

Whiteside TL (2010) Immune responses to malignancies. J Allergy Clin Immunol 125:S272–S283PubMedCrossRef

45.

Knutson KL, Disis ML, Salazar LG (2007) CD4 regulatory cells in human cancer pathogenesis. Cancer Immunol Immunother 56:271–285PubMedCrossRef

Title: The Involvement of RCAS1 in Creating a Suppressive Tumor Microenvironment in Patients with Salivary Gland Adenocarcinoma
Authors: Magdalena Dutsch-Wicherek
Agata Lazar
Romana Tomaszewska
Publication date: 01-04-2011
Publisher: Springer Netherlands
Published in: Cancer Microenvironment / Issue 1/2011
Print ISSN: 1875-2292
Electronic ISSN: 1875-2284
DOI: https://doi.org/10.1007/s12307-010-0051-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

Microdialysis Combined with Proteomics for Protein Identification in Breast Tumor Microenvironment In Vivo

Effect of Increased Extracellular Ca++ on Microvesicle Production and Tumor Spheroid Formation

Myeloid Cells in Cancer Progression: Unique Subtypes and Their Roles in Tumor Growth, Vascularity, and Host Immune Suppression

The Potential Role of MT and Vimentin Immunoreactivity in the Remodeling of the Microenvironment of Parotid Adenocarcinoma

Differential Inductive Signaling of CD90+ Prostate Cancer-Associated Fibroblasts Compared to Normal Tissue Stromal Mesenchyme Cells

Lumican Reduces Tumor Growth Via Induction of Fas-Mediated Endothelial Cell Apoptosis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer